Eligard three-month injectable
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Three-month sustained-release Eligard (leuprolide acetate for injectable suspension) 22.5 mg receives FDA approval July 24 for the palliative treatment of advanced prostate cancer. Once-monthly 7.5 mg Eligard was approved Jan. 23 and launched in May. Physicians often start patients on a monthly leuprolide formulation and then switch responding patients to a 90- or 120-day product (Pharmaceutical Approvals Monthly, February 2002, p. 3
You may also be interested in...
Robust Trial Transparency Strategy Boosts Patient Engagement
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
Medtronic’s Perfusion System Recall Is The 5th In 2 Months
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.
US House Co-signs Banking For Hemp Industry
House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.